The federal government said GenomeDx billed Medicare for its Decipher Biopsy prostate cancer genome classifier on behalf of patients who didn't need the test.
The infringement relates to US patents held by the University of Chicago and exclusively licensed to Bio-Rad.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.
The company agreed to settle a lawsuit alleging it improperly billed government health plans for its genetic tests.
The settlement requires that Curiox refrain from saying that one of its products has equivalent or better sensitivity and reproducibility than a Luminex system.
The deal ends an investigation by the SEC into certain accounting practices by Alere's foreign subsidiaries. The company also consented to a cease-and-desist order.
The Wall Street Journal reports that the erstwhile partners have reached a settlement of more than $25 million.
In a recent regulatory filing, Thermo disclosed that it acquired Core Informatics for $94 million and Finesse Solutions for $220 million.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.